Giovanni Barosi

TL;DR: Screening was a cost-effective strategy, since it provided 2 additional quality-adjusted days of life per patient at the cost of $12,833 per quality- adjusted year of life saved, as compared to standard management, however, screening was not cost- effective in patients who were predicted to incur fatal bleeding at a rate higher than 0.34% per year.

TL;DR: A group discussion among an ad hoc expert panel producing recommendations on the appropriateness of clinical decisions about the indication for NGS, the performance characteristics of NGS platforms, and the therapeutic changes that could be applied based on the use of N GS in CML are reported.

TL;DR: The JAK2V617F mutational status and mutated allele burden were evaluated in 65 patients with post-poly-cythemia vera or post-essential thrombocythemia myelofibrosis (PPV/PET-MF) and it is concluded that presence and burden of JAK1v617F mutation provide little clinically relevant information in patients with PPV/ PET-MF.

TL;DR: Analysis of efficacy outcomes of patients with myelofibrosis in the control arms from the two phase 3 COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (COMFORT) studies suggests that non–Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared with placebo.

TL;DR: Close agreement between experimental and theoretical data proved that the model can describe iron kinetics in sideroblastic anaemia and found ineffective erythropoiesis was found to be the major factor in the production of the anaemia.